Switzerland · Delayed Price · Currency is CHF Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of CHF 227.71 billion. The enterprise value is 261.48 billion.
| Market Cap | 227.71B |
| Enterprise Value | 261.48B |
Important Dates
The next confirmed earnings date is Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 10, 2026 |
Share Statistics
Novartis AG has 1.90 billion shares outstanding. The number of shares has decreased by -3.34% in one year.
| Current Share Class | 1.90B |
| Shares Outstanding | 1.90B |
| Shares Change (YoY) | -3.34% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.85% |
| Float | 1.86B |
Valuation Ratios
The trailing PE ratio is 22.41 and the forward PE ratio is 15.34. Novartis AG's PEG ratio is 2.12.
| PE Ratio | 22.41 |
| Forward PE | 15.34 |
| PS Ratio | 4.97 |
| PB Ratio | 6.72 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.81 |
| P/OCF Ratio | 15.32 |
| PEG Ratio | 2.12 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.84, with an EV/FCF ratio of 19.31.
| EV / Earnings | 25.37 |
| EV / Sales | 5.71 |
| EV / EBITDA | 13.84 |
| EV / EBIT | 17.44 |
| EV / FCF | 19.31 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 1.17.
| Current Ratio | 0.86 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.17 |
| Debt / EBITDA | 2.10 |
| Debt / FCF | 2.92 |
| Interest Coverage | 13.36 |
Financial Efficiency
Return on equity (ROE) is 30.35% and return on invested capital (ROIC) is 18.78%.
| Return on Equity (ROE) | 30.35% |
| Return on Assets (ROA) | 10.25% |
| Return on Invested Capital (ROIC) | 18.78% |
| Return on Capital Employed (ROCE) | 20.57% |
| Weighted Average Cost of Capital (WACC) | 6.26% |
| Revenue Per Employee | 608,606 |
| Profits Per Employee | 136,948 |
| Employee Count | 75,267 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid 2.24 billion in taxes.
| Income Tax | 2.24B |
| Effective Tax Rate | 17.88% |
Stock Price Statistics
The stock price has increased by +22.46% in the last 52 weeks. The beta is 0.49, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +22.46% |
| 50-Day Moving Average | 123.21 |
| 200-Day Moving Average | 119.75 |
| Relative Strength Index (RSI) | 50.51 |
| Average Volume (20 Days) | 3,880,651 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of CHF 45.81 billion and earned 10.31 billion in profits. Earnings per share was 5.34.
| Revenue | 45.81B |
| Gross Profit | 34.34B |
| Operating Income | 15.00B |
| Pretax Income | 12.54B |
| Net Income | 10.31B |
| EBITDA | 18.66B |
| EBIT | 15.00B |
| Earnings Per Share (EPS) | 5.34 |
Balance Sheet
The company has 6.16 billion in cash and 39.60 billion in debt, with a net cash position of -33.45 billion or -17.60 per share.
| Cash & Cash Equivalents | 6.16B |
| Total Debt | 39.60B |
| Net Cash | -33.45B |
| Net Cash Per Share | -17.60 |
| Equity (Book Value) | 33.89B |
| Book Value Per Share | 17.66 |
| Working Capital | -3.55B |
Cash Flow
In the last 12 months, operating cash flow was 14.86 billion and capital expenditures -1.32 billion, giving a free cash flow of 13.54 billion.
| Operating Cash Flow | 14.86B |
| Capital Expenditures | -1.32B |
| Depreciation & Amortization | 3.75B |
| Net Borrowing | 13.62B |
| Free Cash Flow | 13.54B |
| FCF Per Share | 7.13 |
Margins
Gross margin is 74.98%, with operating and profit margins of 32.75% and 22.50%.
| Gross Margin | 74.98% |
| Operating Margin | 32.75% |
| Pretax Margin | 27.38% |
| Profit Margin | 22.50% |
| EBITDA Margin | 40.74% |
| EBIT Margin | 32.75% |
| FCF Margin | 28.84% |
Dividends & Yields
This stock pays an annual dividend of 3.70, which amounts to a dividend yield of 3.09%.
| Dividend Per Share | 3.70 |
| Dividend Yield | 3.09% |
| Dividend Growth (YoY) | 5.71% |
| Years of Dividend Growth | 28 |
| Payout Ratio | 71.08% |
| FCF Payout Ratio | 51.92% |
| Buyback Yield | 3.34% |
| Shareholder Yield | 6.42% |
| Earnings Yield | 4.53% |
| FCF Yield | 5.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novartis AG is 125.70, which is 4.93% higher than the current price. The consensus rating is "Hold".
| Price Target | 125.70 |
| Price Target Difference | 4.93% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 4.83% |
| EPS Growth Forecast (3Y) | 6.45% |
Stock Splits
The last stock split was on May 7, 2001. It was a forward split with a ratio of 40.
| Last Split Date | May 7, 2001 |
| Split Type | Forward |
| Split Ratio | 40 |
Scores
Novartis AG has an Altman Z-Score of 3.36 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.36 |
| Piotroski F-Score | 5 |